Lack of Significant Interactions Between Clopidogrel and Proton Pump Inhibitor Therapy: Meta-Analysis of Existing Literature
- First Online:
- 811 Downloads
Published data regarding the effect of concomitant clopidogrel and proton pump inhibitor (PPI) therapy on cardiovascular outcomes have been conflicting.
To perform an updated meta-analysis in order to determine changes in risk differences (RD) between primary and secondary outcome analyses.
Primary analysis was based on definite vascular outcomes, including all cause mortality, cardiac death, myocardial infarction, and/or stroke. Secondary analysis also incorporated probable cardiac events, which included re-hospitalization for cardiac symptoms or revascularization procedures. RD were combined using a random-effects model.
We reviewed 1,204 publications of which 26 studies (16 published articles, 10 abstracts) met inclusion criteria. The meta-analysis of outcomes from the two randomized controlled trials did not show an increased risk (RD 0.0, 95% CI −0.01, 0.01) for adverse outcomes. The meta-analysis of primary outcomes showed a RD of 0.02 (95% CI 0.01, 0.03) for all studies. The meta-analysis for secondary outcomes yielded a RD of 0.02 (95% CI 0.01–0.04) based on 19 published papers and abstracts. When primary and secondary outcomes were combined, the meta-analysis for published papers yielded an overall RD of 0.05 (95% CI 0.03–0.06).
In patients using concomitant clopidogrel and PPI therapy, the risk of adverse cardiac outcomes was 0% based on data from well-controlled randomized trials. Data from retrospective studies and the addition of probable vascular events significantly increased the RD estimates, likely due to lack of adjustment for potential confounders.
KeywordsProton pump inhibitor Clopidogrel Meta-analysis
- 5.Aubert RE, Epstein RS, Teagarden JR, et al. Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel medco outcomes study. Circulation. 2008;118:S815.Google Scholar
- 6.Dunn SP, Macaulay TE, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation. 2008;118:S815.Google Scholar
- 11.Zairis MN, Patsourakos NG, Makrygiannis SS, et al. The impact of oral proton pump inhibitors on the effectiveness of combined aspirin and clopidogrel drug therapy during the first year after elective coronary stenting. Eur Heart J. 2008;29:134.Google Scholar
- 12.Tsiaousis GZ, Zairis MN, Patsourakos NG, et al. Oral proton pump inhibitors and their impact on the effectiveness of dual anti-platelet therapy during the first year after elective coronary stenting. J Am Coll Cardiol. 2009;53:A335.Google Scholar
- 14.Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909–1917.Google Scholar
- 16.Banerjee S, Weideman RA, Weideman MW, et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol. 2011;107:871–878.Google Scholar
- 20.van Boxel OS, van Oijen MG, Hagenaars MP, Smout AJ, Siersema PD. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large dutch cohort study. Am J Gastroenterol. 2010;105:2430–2436.Google Scholar
- 25.Tentzeris I, Jarai R, Farhan S, Brozovic I, Smetana P, Geppert A, et al. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost. 2010;104:1211–1218.Google Scholar
- 26.Torguson R, Chou C, Kaneshige K, et al. Does proton pump inhibitor use following percutaneous coronary intervention with drug-eluting stents impact clinical outcome? Circulation. 2009;120:S968.Google Scholar
- 27.Zairis MN, Tsiaousis GZ, Patsourakos NG, Georgilas AT, Kontos CF, Adamopoulou EN, et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol. 2010;26:54–57.Google Scholar
- 32.Harjai K, Orshaw P, Boura J, Rogers G. Six-month outcomes with or without proton-pump inhibitors after successful PCI: insights from the Guthrie PCI registry. J Am Coll Cardiol. 2010;55:A179.Google Scholar
- 33.Ching G, Li DD, McKay R, Mather J, Lundbye J. Proton pump inhibitors increase major adverse cardiac events among post percutaneous coronary intervention patients on clopidogrel. Circulation. 2009;120:S936–S937.Google Scholar
- 34.Ramirez JF, Selzer F, Chakaprani R, et al. Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: the NHLBI dynamic registry. J Am Coll Cardiol. 2009;53:A27.Google Scholar
- 35.Banerjee S, Varghese C, Weideman RA, Weideman MW, Little BB. Proton pump inhibitors increase the risk of major adverse cardiovascular events in post-PCI patients who are on clopidogrel. Eur Heart J. 2009;30:P653.Google Scholar
- 37.Sweeny JM, Kini A, Muntner P, Jakkula M, Farkouh M, Sharma S. Mortality associated with proton pump inhibitors following percutaneous coronary interventions with drug eluting stents. Circulation. 2009;120:S936.Google Scholar